Alzheimer’s

Abbott
Accuray
Allergan
Alzheimer’s
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cardinal Health
Cardiology
Danaher
Dermatology
Diabetes
DSM-5
Editorial
Edwards Lifesciences
Elekta
Eli Lilly
Endo Health Solutions
Forest Laboratories
Gilead
GlaxoSmithKline
Health Care
Hematology
Hepatitis
HIV/AIDS
Hospital
Intercept
Interviews
Intuitive Surgical
Layman's Terms
McLaren Health Care
Medical
Merck
Mylan
Novartis
Nursing
Oncology
Pfizer
Pharmaceuticals
Physician Commentary
Press Releases
Psych Drugs
Psychiatry
Regeneron
Roche
Sangamo
Sanofi
Surgical
Technology
Valeant Pharmaceuticals
Varian

August 9, 2013

Pfizer Pipeline: New Drugs In The Making

Pfizer Pipeline: New Drugs In The Making (August 9, 2013) – Pfizer is in the process of developing the following new drugs that may prove very useful in the field of Psychiatry drugs: AAC-001 (Phase 2): New Alzheimer’s disease vaccine AAB-003 (Phase 1): New biologic Alzheimer’s treatment SAM-760 (Phase 3): New Alzheimer’s treatment PF-04958242 (Phase […]